Latest news
{{'2025-09-18T08:45:49Z' | dateFormatFilter}}
Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
{{'2025-09-17T21:05:17Z' | dateFormatFilter}}
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
{{'2025-09-16T10:00:47Z' | dateFormatFilter}}
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
